Business
Sensorion Announces €60 Million Financing With a €20M Strategic Investment from Sanofi and Support from Global Healthcare Specialists To Advance Genetic Medicine Pipeline
MONTPELLIER, France, January 28, 2026--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced a €60 million offering reserved to specific categories of investors (the "Reserved Offering") through the issuance of 214,285,714 new ordinary shares of the Company (the "New Shares") at a price per New Share of €0.28 (the "Subscriptio
About this update from Sensorion Sas
[{"type":"list","items":[{"val":[{"type":"text","content":"Sanofi’s investment marks the entry of a strategic shareholder","length":62,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Support from existing investors Redmile Group, Artal, which is advised by Invus, and Sofinnova Partners","length":103,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Participation from leading U.S. Healthcare Specialists funds including Cormorant Asset Management, Coastlands Capital and Sphera Healthcare","length":139,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Cash runway extended until H1 2027, supporting key catalysts including SENS-601 (GJB2-GT) CTA/IND approval and first cohort enrollment, as well as the continued clinical advancement of SENS-501","length":193,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":497,"olType":false},{"type":"text","content":"MONTPELLIER, France, January 28, 2026--(BUSINESS WIRE)--Regulatory News:","length":72,"tagName":"p"},{"type":"text","content":"Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced a €60 million offering reserved to specific categories of investors (the "Reserved Offering") through the issuance of 214,285,714 new ordinary shares of the Company (the "New Shares") at a price per New Share of €0.28 (the "Subscription Price") to the benefit of Sanofi for €20 million, and Redmile Group, Artal, which is advised by Invus, and Sofinnova Partners, existing shareholders, and other investors including Cormorant Asset Management, Coastlands Capital and Sphera Healthcare, for €40 million. The settlement-delivery of the Reserved Offering is expected to take place around January 30th, 2026, subject to customary conditions.","length":877,"tagName":"p"},{"type":"text","content":"Sanofi’s investment and participating investors will drive the progression of the genetic medicine pipeline, notably SENS-601 (GJB2-GT). This funding supports key catalysts for the program which targets hearing loss associated with GJB2 mutations, including CTA/IND approval and the enrollment of the first clinical cohort.","length":323,"tagName":"p"},{"type":"text","content":"SENS-601 (GJB2-GT) will be the...